Cardio Diagnostics Holdings, Inc. (CDIO)
| Market Cap | 23.53M |
| Revenue (ttm) | 17,065 |
| Net Income (ttm) | -8.38M |
| Shares Out | 21.59M |
| EPS (ttm) | -0.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 85,228 |
| Open | 1.010 |
| Previous Close | 1.020 |
| Day's Range | 1.000 - 1.090 |
| 52-Week Range | 0.171 - 3.560 |
| Beta | 4.97 |
| Analysts | Buy |
| Price Target | 8.00 (+633.95%) |
| Earnings Date | May 13, 2024 |
About CDIO
Cardio Diagnostics Holdings, Inc., an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. The company was founded in 2017 and is headquartered in Chicago, Illinois. [Read more]
Financial Performance
In 2023, CDIO's revenue was $17,065, an increase of 1696.32% compared to the previous year's $950. Losses were -$8.38 million, 79.7% more than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for CDIO stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 633.95% from the latest price.
News
Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan
CHICAGO--(BUSINESS WIRE)--Exponential Health adopts Cardio Diagnostics' AI-driven epigenetic-genetic tests marking a new era in personalized and preventive cardiac care.
Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre
CHICAGO--(BUSINESS WIRE)--This collaboration aims to expand access to Cardio Diagnostics' industry-leading, AI-enabled precision cardiovascular diagnostic tests.
Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiology's 73rd Annual Scientific Session
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will showcase its HeartRisk and Actionable Clinical Intelligence platforms at the ACC's 73rd Annual Scientific Session.
Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has announced the issuance of its second U.S. patent.
Cardio Diagnostics Holdings, Inc. Expands HeartRisk™ Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced today the nationwide rollout and a significant expansion of its groundbreaking HeartRisk™ platform.
Cardio Diagnostics Holdings, Inc. Expands Partnership with Family Medicine Specialists to Bring Its Specialty Cardiology Tests to Select Walmart Supercenters
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' AI-driven epigenetic-genetic blood tests will be available Q2 2024 inside the Walmart Supercenter in Round Lake Beach, Illinois.
Houston-Based resTOR Longevity Clinic to Offer Cardio Diagnostics' AI-Driven Epigenetic-Genetic Heart Disease Tests
CHICAGO--(BUSINESS WIRE)--resTOR Longevity Clinic will offer Cardio Diagnostics' blood-based epigenetic-genetic cardiovascular disease tests.
Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor.
Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced that India's Patent Office has granted a patent to the University of Iowa Research Foundation under patent number 484488.
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has unveiled HeartRisk, the Company's groundbreaking employer cardiovascular disease risk intelligence platform.
Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has unveiled HeartRisk, the Company's groundbreaking employer cardiovascular disease risk intelligence platform.
American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event
CHICAGO--(BUSINESS WIRE)--The AMA has granted and assigned Cardio Diagnostics a dedicated CPT® PLA for the company's AI-driven CHD event risk assessment test, Epi+Gen CHD.
American Medical Association (AMA) Grants Cardio Diagnostics Holdings, Inc.'s AI-Powered Coronary Heart Disease Detection Test, PrecisionCHD, a Dedicated CPT PLA Reimbursement Code
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced that the AMA has assigned a dedicated CCPT® PLA) for the company's AI-driven CHD detection test, PrecisionCHD.
Cardio Diagnostics Holdings, Inc. Appoints Biotechnology Investor, Executive & Serial Entrepreneur Paul Burton to its Board of Directors
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director.
Cardio Diagnostics Holdings, Inc. Regains Nasdaq Minimum Bid Price Requirement
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. today announced it has regained Nasdaq minimum bid price requirement.
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Convenes Cardiovascular Care & Risk Roundtable at the 42nd Annual J.P. Morgan Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will be presenting a roundtable session on cardiovascular care and risk at the 42nd Annual J.P. Morgan Healthcare Conference.
Cardio Diagnostics Holdings, Inc's Convenes Cardiovascular Care & Risk Roundtable at the 42nd Annual J.P. Morgan Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will be presenting a roundtable session on cardiovascular care and risk at the 42nd Annual J.P. Morgan Healthcare Conference.
American Medical Association is Reviewing Cardio Diagnostics Holdings, Inc's Integrated Epigenetic-Genetic Cardiovascular Medicine Tests for CPT PLA Codes
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the AMA CPT Editorial Panel is reviewing its Epi+Gen CHD and PrecisionCHD tests for CPT PLA codes.
Cardio Diagnostics Holdings, Inc. Announces Breakthrough in Coronary Heart Disease Detection with PrecisionCHD Test, Published in the Journal of the American Heart Association
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the publication of its groundbreaking study in the Journal of the American Heart Association (JAHA),.
Family Medicine Specialists Selects Cardio Diagnostics' Epigenetic-Genetic Tests for Assessing Heart Attack Risk for its BlueCross BlueShield Patients
CHICAGO--(BUSINESS WIRE)--Family Medicine Specialists has selected Cardio Diagnostics' tests to identify patients at risk for coronary heart disease events.
Cardio Diagnostics Holdings, Inc Receives Innovative Technology Contract from Vizient for Its Novel AI-Driven Precision Heart Disease Tests – Epi+Gen CHD & PrecisionCHD
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced its AI-driven molecular heart disease tests has received an Innovation Technology contract from Vizient, Inc.
Cardio Diagnostics Holdings, Inc and Aimil Ltd Join Forces to Introduce Cardiovascular Epigenetic Technologies to India
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced it has entered into a Supply and Distribution Agreement with Aimil Ltd.
Cardio Diagnostics Holdings, Inc Launches New Lab and Fulfillment Center, Paving Way for Expanded Testing Capacity, Reduced Costs, Reduced Turnaround Time and Improved Margins
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the launch of the Company's new integrated facility in Iowa City, Iowa.
Cardio Diagnostics Publishes Novel and Scalable Pathways to Enhance Global Coronary Heart Disease Care through Precision Epigenetics in Epigenomics
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics and Dr. Damon Broyles published an article on scalable pathways that leverage precision epigenetics to revolutionize CHD.
Cardio Diagnostics Holdings, Inc. and Truckers Health Network Enter Into a Strategic Collaboration to Accelerate Cardiovascular Health Initiatives in the Trucking Industry
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced a collaboration with Truckers Health Network to Accelerate cardiovascular health initiatives in the trucking industry.